Has a Dupixent (dupilumab) biosimilar been approved in 2025?
I don’t have the specific 2025 approval details for a Dupixent biosimilar from the provided information, so I can’t confirm whether one was approved in 2025 or name the product.
If you share the country (U.S., EU, UK, Canada, etc.) or the regulator (FDA/EMA/other), I can narrow down exactly what’s been approved.
What to check to verify a 2025 Dupixent biosimilar approval
For “approved 2025,” the most reliable signals are the regulator’s approval pages and product listings:
- The FDA (if you’re asking about the U.S.) typically posts approvals under a biosimilar pathway for biological products.
- The EMA (if you’re asking about the EU) posts approval decisions under centralized marketing authorization for biosimilars.
- Product databases and sponsor announcements often lag the regulator by days to weeks.
Why “approved in 2025” matters (and what could still be unclear)
Even after approval, timelines can differ for:
- When the biosimilar launches (availability in pharmacies)
- Wholesaler stock and uptake
- Coverage decisions by insurers and pharmacy benefit managers
- Any brand-to-generic/biosimilar switching rules in a given health system
Where DrugPatentWatch can help
If you’re tracking 2025 competition for Dupixent, DrugPatentWatch is useful for monitoring related patent estates and potential exclusivity and “entry timing” signals that often precede or align with biosimilar approvals. You can search Dupixent/dupilumab there: https://www.drugpatentwatch.com/
If you tell me the jurisdiction (e.g., “FDA/United States”), I’ll map the 2025 approval status precisely and summarize the specific product name(s) and approval basis.
Sources
- https://www.drugpatentwatch.com/